Related Experiment Video
Updated: Feb 4, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Bilateral anterior uveitis after immunotherapy for malignant melanoma
Chia-Jui Chang1, Shih-Jen Chen1,2, De-Kuang Hwang1,2
1Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan.
Abstract:
Immune checkpoint blockade therapy is relatively a new treatment for cancer which has shown promising results. However, immune-related side effects including uveitis have occasionally been reported during this therapy. Herein, we report the case of a 65-year-old male who suffered bilateral anterior uveitis after immune checkpoint blockade therapy with pembrolizumab and ipilimumab for malignant melanoma. His symptoms and signs improved after topical treatment with corticosteroids. Clinicians should be aware that uveitis can be an immune-related adverse event of immunotherapy.
Related Concept Videos
Tumor Immunotherapy
Muscles of the Anterior Neck

